Al Khayyat has 13 years of industry experience. He leads his family business, which was founded in the U.A.E. in 1982 by Saad Al Khayyat, focusing on the sale and distribution of pharmaceutical and medical products. The group partners with patient support providers such as AXIOS and IQVIA. AKI has three healthcare subsidiaries: AKI MedLab, AKI Pharma, and BinSina Pharmacy. In 2022, AKI Pharma expanded its portfolio to cover more diverse therapy areas, including gene therapy, biosimilars, oncology, and specialty, as well as rare and ultra-rare diseases. It also expanded BinSina Pharmacy in Oman and relaunched its mobile app.